Altered type II interferon precedes autoantibody accrual and elevated type i interferon activity prior to systemic lupus erythematosus classification

Annals of the Rheumatic Diseases

Volumn 75, Issue 11, 2016, Pages 2014-2021

  Munroe, Melissa E ^a   Lu, Rufei ^a,b   Zhao, Yan D ^c   Fife, Dustin A ^a   Robertson, Julie M ^a   Guthridge, Joel M ^a   Niewold, Timothy B ^d   Tsokos, George C ^e   Keith, Michael P ^f   Harley, John B ^g   James, Judith A ^a,b  

^a OKLAHOMA MEDICAL RESEARCH FOUNDATION   (United States)

^b UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER   (United States)

^d MAYO GRADUATE SCHOOL   (United States)

^e HARVARD MEDICAL SCHOOL   (United States)

^f WALTER REED ARMY MEDICAL CENTER   (United States)

^g VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Autoantibodies; Autoimmunity; Chemokines; Cytokines; Systemic Lupus Erythematosus

Indexed keywords

AUTOANTIBODY; GAMMA INTERFERON; INTERFERON; MONOCYTE CHEMOTACTIC PROTEIN 3; ALPHA INTERFERON; B CELL ACTIVATING FACTOR;

ACCURACY; ADULT; AFRICAN AMERICAN; ANTIBODY BLOOD LEVEL; ARTICLE; CHROMATIN; CLINICAL EVALUATION; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; EUROPEAN AMERICAN; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; SPLICEOSOME; SYSTEMIC LUPUS ERYTHEMATOSUS; BLOOD; CASE CONTROL STUDY; IMMUNOLOGY; LUPUS ERYTHEMATOSUS, SYSTEMIC; MULTIVARIATE ANALYSIS; TIME FACTOR;

ADULT; AUTOANTIBODIES; B-CELL ACTIVATING FACTOR; CASE-CONTROL STUDIES; FEMALE; HUMANS; INTERFERON TYPE I; INTERFERON-ALPHA; INTERFERON-GAMMA; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MULTIVARIATE ANALYSIS; TIME FACTORS;

EID: 84962191041     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2015-208140     Document Type: Article

References (41)

1. Stahl Hallengren C, Nived O, Sturfelt G. Outcome of incomplete systemic lupus erythematosus after 10 years. Lupus 2004;13:85-8.
2. Heinlen LD, McClain MT, Merrill J, et al. Clinical criteria for systemic lupus erythematosus precede diagnosis, and associated autoantibodies are present before clinical symptoms. Arthritis Rheum 2007;56:2344-51.
3. Arbuckle MR, McClain MT, Rubertone MV, et al. Development of autoantibodies before the clinical onset of systemic lupus erythematosus. N Engl J Med 2003;349:1526-33.
4. Satoh M, Chan EK, Ho LA, et al. Prevalence and sociodemographic correlates of antinuclear antibodies in the United States. Arthritis Rheum 2012;64:2319-27.
5. Niewold TB. Interferon alpha as a primary pathogenic factor in human lupus. J Interferon Cytokine Res 2011;31:887-92.
6. Weckerle CE, Franek BS, Kelly JA, et al. Network analysis of associations between serum interferon-α activity, autoantibodies, and clinical features in systemic lupus erythematosus. Arthritis Rheum 2011;63:1044-53.
7. Lopez P, Scheel-Toellner D, Rodriguez-Carrio J, et al. Interferon-Alpha-induced B-lymphocyte stimulator expression and mobilization in healthy and systemic lupus erthymatosus monocytes. Rheumatology (Oxford) 2014;53:2249-58.
8. Vincent FB, Morand EF, Schneider P, et al. The BAFF/APRIL system in SLE pathogenesis. Nat Rev Rheumatol 2014;10:365-73.
9. Lauwerys BR, Ducreux J, Houssiau FA. Type I interferon blockade in systemic lupus erythematosus: where do we stand? Rheumatology (Oxford) 2014;53:1369-76.
10. Moser KL, Kelly JA, Lessard CJ, et al. Recent insights into the genetic basis of systemic lupus erythematosus. Genes Immun 2009;10:373-9.
11. Schroder K, Hertzog PJ, Ravasi T, et al. Interferon-gamma: An overview of signals, mechanisms and functions. J Leukoc Biol 2004;75:163-89.
12. Harigai M, Kawamoto M, Hara M, et al. Excessive production of IFN-gamma in patients with systemic lupus erythematosus and its contribution to induction of B lymphocyte stimulator/B cell-Activating factor/TNF ligand superfamily-13B. J Immunol 2008;181:2211-19.
13. Walker JA, Barlow JL, McKenzie AN. Innate lymphoid cells-how did we miss them? Nat Rev Immunol 2013;13:75-87.
14. Chen P, Vu T, Narayanan A, et al. Pharmacokinetic and pharmacodynamic relationship of AMG 811, an anti-IFN-γ IgG1 monoclonal antibody, in patients with systemic lupus erythematosus. Pharm Res 2015;32:640-53.
15. Yellin M, Paliienko I, Balanescu A, et al. A phase II, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of MDX-1100, a fully human anti-CXCL10 monoclonal antibody, in combination with methotrexate in patients with rheumatoid arthritis. Arthritis Rheum 2012;64:1730-9.
16. Bruner BF, Guthridge JM, Lu R, et al. Comparison of autoantibody specificities between traditional and bead-based assays in a large, diverse collection of patients with systemic lupus erythematosus and family members. Arthritis Rheum 2012;64:3677-86.
17. Munroe ME, Vista ES, Guthridge JM, et al. Pro-inflammatory adaptive cytokines and shed tumor necrosis factor receptors are elevated preceding systemic lupus erythematosus disease flare. Arthritis Rheumatol 2014;66:1888-99.
18. Niewold TB, Hua J, Lehman TJ, et al. High serum IFN-Alpha activity is a heritable risk factor for systemic lupus erythematosus. Genes Immun 2007;8:492-502.
19. Hua J, Kirou K, Lee C, et al. Functional assay of type I interferon in systemic lupus erythematosus plasma and association with anti-RNA binding protein autoantibodies. Arthritis Rheum 2006;54:1906-16.
20. Yamamoto T, Mizoguchi Y, Kaneno H, et al. Serum immunoglobulin G subclass levels and estimated clinical severity caused by possible influenza A (H1N1) pdm 2009 infection. J Infect Chemother 2013;19:833-42.
21. Hooper D, Coughlan J, Mullen MR. Structural equation modelling: guidelines for determining model fit. Electron J Bus Res Methods 2008;6:53-60.
22. Genuer R, Poggi JM, Tuleau-Malot C. Variable selection using random forests. Pattern Recogn Lett 2010;31:2225-36.
23. Li QZ, Zhou J, Lian Y, et al. Interferon signature gene expression is correlated with autoantibody profiles in patients with incomplete lupus syndromes. Clin Exp Immunol 2010;159:281-91.
24. Eloranta ML, Barbasso Helmers S, Ulfgren AK, et al. A possible mechanism for endogenous activation of the type I interferon system in myositis patients with anti-Jo-1 or anti-Ro 52/anti-Ro 60 autoantibodies. Arthritis Rheum 2007;56:3112-24.
25. Mathsson L, Ahlin E, Sjowall C, et al. Cytokine induction by circulating immune complexes and signs of in-vivo complement activation in systemic lupus erythematosus are associated with the occurrence of anti-Sjogrens syndrome A antibodies. Clin Exp Immunol 2007;147:513-20.
26. Savarese E, Chae OW, Trowitzsch S, et al. U1 small nuclear ribonucleoprotein immune complexes induce type I interferon in plasmacytoid dendritic cells through TLR7. Blood 2006;107:3229-34.
27. Tian J, Avalos AM, Mao SY, et al. Toll-like receptor 9-dependent activation by DNA-containing immune complexes is mediated by HMGB1 and RAGE. Nat Immunol 2007;8:487-96.
28. Kil LP, Hendriks RW. Aberrant B cell selection and activation in systemic lupus erythematosus. Int Rev Immunol 2013;32:445-70.
29. Choi J, Kim ST, Craft J. The pathogenesis of systemic lupus erythematosus-An update. Curr Opin Immunol 2012;24:651-7.
30. Peng SL, Szabo SJ, Glimcher LH. T-bet regulates IgG class switching and pathogenic autoantibody production. Proc Natl Acad Sci USA 2002;99: 5545-50.
31. Szodoray P, Nakken B, Barath S, et al. Progressive divergent shifts in natural and induced T-regulatory cells signify the transition from undifferentiated to definitive connective tissue disease. Int Immunol 2008;20:971-9.
32. Mosca M, Neri R, Bencivelli W, et al. Undifferentiated connective tissue disease: Analysis of 83 patients with a minimum followup of 5 years. J Rheumatol 2002;29:2345-9.
33. Kiefer K, Oropallo MA, Cancro MP, et al. Role of type I interferons in the activation of autoreactive B cells. Immunol Cell Biol 2012;90:498-504.
34. Deane KD, ODonnell CI, Hueber W, et al. The number of elevated cytokines and chemokines in preclinical seropositive rheumatoid arthritis predicts time to diagnosis in an age-dependent manner. Arthritis Rheum 2010;62: 3161-72.
35. Hughes-Austin JM, Deane KD, Derber LA, et al. Multiple cytokines and chemokines are associated with rheumatoid arthritis-related autoimmunity in first-degree relatives without rheumatoid arthritis: Studies of the Aetiology of Rheumatoid Arthritis (SERA). Ann Rheum Dis 2013;72:901-7.
36. Costedoat-Chalumeau N, Dunogue B, Morel N, et al. Hydroxychloroquine: A multifaceted treatment in lupus. Presse medicale 2014;43(6 Pt 2):e167-80.
37. Akhavan PS, Su J, Lou W, et al. The early protective effect of hydroxychloroquine on the risk of cumulative damage in patients with systemic lupus erythematosus. J Rheumatol 2013;40:831-41.
38. James JA, Kim-Howard XR, Bruner BF, et al. Hydroxychloroquine sulfate treatment is associated with later onset of systemic lupus erythematosus. Lupus 2007;16: 401-9.
39. Rahman P, Gladman DD, Urowitz MB, et al. Early damage as measured by the SLICC/ACR damage index is a predictor of mortality in systemic lupus erythematosus. Lupus 2001;10:93-6.
40. Urowitz MB, Gladman DD, Ibanez D, et al. Evolution of disease burden over five years in a multicenter inception systemic lupus erythematosus cohort. Arthritis Care Res 2012;64:132-7.
41. Urowitz MB, Gladman DD, Ibanez D, et al. American College of Rheumatology criteria at inception, and accrual over 5 years in the SLICC inception cohort. J Rheumatol 2014;41:875-80.